#China #Beijing #Hepatitis B #Hepatitis D #Libevitug

Hepatitis D: An Overlooked Health Crisis

On World Hepatitis Day 2026, the focus has shifted towards Hepatitis D (HDV), a severe form of chronic viral hepatitis that predominantly affects individuals already suffering from Hepatitis B. Despite affecting approximately 12 million people globally, HDV is a condition that is alarmingly underrecognized.

The Global Challenge

The World Health Organization (WHO) estimates that HDV has a significant presence, especially in Central Asia, where a high-prevalence belt stretches from Mongolia through western China, Afghanistan, and into parts of the Middle East. Unfortunately, the available national epidemiological data from these regions are insufficient, raising concerns that the actual burden of HDV may be grossly underestimated. Recent studies indicate alarming prevalence rates: about 13% of Hepatitis B patients in Kazakhstan also have HDV, whereas a staggering 84% of Hepatitis B patients tested in Uzbekistan showed the presence of HDV antibodies.

The Urgency of Early Diagnosis

Early identification of HDV is paramount. Research indicates that without timely detection and intervention, the disease can progress rapidly; patients may see the development of cirrhosis within five years and liver cancer within ten years on average. However, many low- and middle-income countries face significant barriers to confirmatory HDV RNA testing, leaving many infections undiagnosed and thus complicating measures to quantify the disease's true impact.

Limited Treatment Options

Currently, the options for treating HDV are limited. As of July 2026, worldwide approval exists for only two HDV-specific therapies, none of which are accessible in Central Asia. This scarcity of treatment has forced many patients from the region to seek medical attention in cities like Beijing and Urumqi. In a significant development, Libevitug became the first treatment for chronic Hepatitis D to receive conditional approval in China in January 2026. This innovative monoclonal antibody has shown promising efficacy in blocking viral entry and improving liver condition without negatively affecting normal bile acid transport.

Raising Awareness and Collaboration

According to Bin Chen, CEO of Huahui Health, which is spearheading the development and distribution of Libevitug, improving care for Hepatitis D will necessitate ongoing cooperation across the Central Asian region. Increasing public awareness, facilitating broader access to testing, and promoting scientific collaboration are essential steps needed to elevate HDV care from the shadows into the mainstream healthcare dialogue. He asserts, "We are dedicated to partnering with relevant organizations to foster scientific exchange and clinical research, aiming for long-term benefits for patients suffering from Hepatitis D."

In conclusion, while Hepatitis D continues to present an overarching health threat for individuals already vulnerable due to Hepatitis B, concerted efforts towards education, timely diagnosis, and treatment access can help mitigate its risks. Raising awareness about this underappreciated disease is crucial as we strive for a future where fewer individuals suffer the consequences of Hepatitis D.